ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pegcetacoplan

Also written as “Pegcetacoplan”, “APL-2” and “PEGCETACOPLAN (APL-2)”.

Its studies are mostly in Geographic Atrophy · Hemoglobinuria, Paroxysmal · Glomerulonephritis, Membranoproliferative · Anemia, Hemolytic, Autoimmune · Macular Degeneration, led by 4 companies.

Drug pagePegcetacoplan: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 10, 201830 company-led studies, 7 open or runningNext primary completion: Jun 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogenits history only244 open or runningphase 3since Apr 10, 2018Oct 8, 2014Jun 25, 2027phase 2 · NCT07215390
Swedish Orphan Biovitrum42 open or runningphase 4since Mar 26, 2026Oct 15, 2021Jan 17, 2031phase 3 · NCT07898774
AbbVieits history only11 open or runningphase 2since Aug 12, 2025Aug 12, 2025Oct 2029phase 2 · NCT07160179
Hoffmann-La Rocheits history only10 open or runningphase 1since Apr 29, 2025Apr 29, 2025none ahead

Also a collaborator on its studies: IQVIA Pty.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Swedish Orphan Biovitrum only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named pegcetacoplanINNProposed as its International Nonproprietary Name in WHO's List 118
  2. Oct 15, 2021First study: phase 3 study in Anemia, Hemolytic, AutoimmuneFirst studyNCT05096403 · 24 enrolled · United States, Austria, Belgium and more
  3. Oct 21, 2021Phase 2 study in Transplant-Associated Thrombotic MicroangiopathyNCT05148299 · 12 enrolled · United States, France, Greece and more
  4. Mar 26, 2026Phase 4 study in GlomerulonephritisNCT07746895 · 150 planned · Australia, Austria, Belgium and more
  5. Oct 21, 2026Phase 3 study in C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)NCT07898774 · 30 planned · Brazil, Canada, Finland and more

Ahead

  1. Jan 17, 2031Primary completion: phase 3 study in C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)NCT07898774
  2. Dec 31, 2031Primary completion: phase 4 study in GlomerulonephritisNCT07746895

TargetBeta

C3 →read by rule
“A pegylated peptide inhibitor of human complement components C3 and C3b, ”NCIt, by rule
“Complement C3 inhibitor”ChEMBL 37, by rule

Other programs on C3

ProgramCompanyFurthest phaseStudies
SSS55rule3SBiophase 11

Studies

All 4 Swedish Orphan Biovitrum leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07898774C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) · Brazil, Canada, Finland and more3RecruitingJan 17, 203130
NCT07746895Glomerulonephritis · Australia, Austria, Belgium and more4RecruitingDec 31, 2031150
NCT05148299Transplant-Associated Thrombotic Microangiopathy · United States, France, Greece and more2CompletedDec 8, 202412
NCT05096403Anemia, Hemolytic, Autoimmune · United States, Austria, Belgium and more3CompletedMay 27, 202424

How it is read

Names in the registry

  • “Pegcetacoplan”, 17 entries
  • “APL-2”, 7 entries
  • “PEGCETACOPLAN (APL-2)”, 2 entries
  • “APL-3007, pegcetacoplan (APL-2)”, 2 entries
  • “Syfovre™”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.